language_icon
EN
HI

Alkem Laboratories Share price

ALKEM

5344

109.00 (2.08%)
NSE
BSE
Last updated on 27 Apr, 2026 | 15:43 IST
Today's High

5486.00

Today's Low

5248.00

52 Week Low

4716.20

52 Week High

5933.50

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Alkem Laboratories Chart

Alkem Laboratories Share Key Metrics

Volume
2.12 L
Market Cap
63895.54 CR
LTQ@LTP
13@5344.00
ATP
5383.85
Var Margin
13.08 %
Circuit Range
4711.5-5758.5
Delivery %
32.96 %
Value
114.22 CR
ASM/GSM
No
Market Lot
1

Summary

27 Apr, 2026 | 15:43 को, Alkem Laboratories का शेयर प्राइस आज ₹5344 पर है, जो दिन के लिए 109.00% की 2.08 दर्शाता है। स्टॉक की इंट्राडे मूवमेंट ₹5248.00 और ₹5486.00 के बीच रही है, जबकि 52‑सप्ताह के आधार पर यह ₹4716.20 से ₹5933.50 तक रही है। ट्रेडिंग गतिविधि के मामले में, Alkem Laboratories ने 212162 शेयरों का वॉल्यूम रिकॉर्ड किया है, जिसका मार्केट कैपिटलाइज़ेशन ₹119565000 है। स्टॉक की एवरेज ट्रेडेड प्राइस ₹538385 है, जबकि लास्ट ट्रेडेड क्वांटिटी एट लास्ट ट्रेडेड प्राइस (LTQ@LTP) 13,534400 रही। यह स्टॉक ₹4711.5-5758.5 की सर्किट रेंज में ट्रेड करता है, और आज का कारोबार मूल्य ₹114.22 CR है। दिन के लिए डिलीवरी परसेंटेज 32.96% रही। इसके अतिरिक्त, Alkem Laboratories वर्तमान में No फ्रेमवर्क के तहत आता है और 1 के मार्केट लॉट साइज़ में ट्रेड करता

Alkem Laboratories Fundamentals

View More
P/E Ratio

26.37

P/B Ratio

4.47

Div. Yield

0.86

Sector P/E

63.82

Sector P/B

3.5

Sec. Div. Yield

0.57

Alkem Laboratories Resistance and Support

Pivot 5335.67

Resistance

First Resistance

5477.84

Second Resistance

5720.67

Third Resistance

5862.84

Support

First Support

5092.84

Second Support

4950.67

Third Support

4707.84

Alkem Laboratories Futures & Options

link_white_icon

Alkem Laboratories Option Chain

View Price, OI, Greeks & More...
View All

28APR26

5361.00

112.50 (2.14%)

26MAY26

5394.00

121.00 (2.29%)

30JUN26

5399.50

74.50 (1.40%)

ALKEM|28APR26 CE 5300.00

71.65

13.35 (22.9%)

ALKEM|28APR26 PE 5350.00

31

-113.6 (-78.56%)

Alkem Laboratories Shareholding Pattern

View More
  • 2016-17
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

51.2%

Mutual Fund

15.57%

Insurance

4.18%

Foreign Institutional Investors

10.15%

Domestic Institutional Investors

1.65%

Retail

17.25%

Others

0%

Total Promoters
MAR '26
51.2%

Alkem Laboratories Corporate Actions

DateAgenda
2026-02-13Quarterly Results & Interim Dividend

Alkem Laboratories News

Alkem Laboratories Limited

Alkem Laboratories received an income tax order from the Deputy Commissioner of Income Tax, Central Circle 8(1), Mumbai, disputing a tax amount of ₹333.38 crores for Assessment Year 2023-24. The company asserts no material financial impact due to available MAT credit and plans to appeal the order, believing it has strong grounds to substantiate its position.
Apr 24 2026 16:04:00

Alkem Laboratories Limited

Alkem Laboratories' CEO & KMP, Dr. Vikas Gupta, has resigned. He will serve until June 30, 2026, to facilitate a smooth transition of responsibilities.
Apr 24 2026 15:04:00

Alkem Laboratories shares crater after CEO Vikas Gupta resigns to pursue new opportunities

Vikas Gupta, CEO of Alkem Laboratories, has resigned from his position to pursue new opportunities, leading to a decline of over 4% in the company's share price in early trade. The company has initiated a handover process for succession.
Apr 24 2026 14:04:00

Alkem Laboratories Limited

Alkem Laboratories incorporated Alkem Pharma Trading FZCO, a wholly-owned subsidiary, in UAE on March 27, 2026. This move aims to strengthen the company's export presence in African, Southeast Asian, and non-UAE markets.
Apr 13 2026 15:04:00

Alkem Laboratories Ltd - 539523 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015- Incorporation Of Wholly Owned Subsidiary Of The Company

Alkem Laboratories incorporated its wholly owned subsidiary, Alkem Pharma Trading FZCO, in Dubai, UAE. This new entity, with a capital of AED 36,70,000, will focus on exporting the company’s pharmaceutical products to African, South East Asian, and non-UAE markets.
Apr 13 2026 15:04:00

Alkem Laboratories Limited

Alkem Laboratories incorporated a wholly-owned subsidiary, Alkem Pharma Trading FZCO, in Dubai, UAE. This new entity, with a subscribed capital of AED 3,670,000, aims to export the company's products to African, South East Asian, and non-UAE markets.
Apr 13 2026 15:04:00

Alkem Laboratories Limited

Alkem Laboratories submitted revised XBRL financial results for Q4 FY25, correcting discrepancies in the initial audited submission. The revised submission includes both standalone and cons. figures for the quarter ended March 31, 2025.
Apr 10 2026 18:04:00

Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Alkem Laboratories launched 'A to Z Daily,' an everyday multivitamin supplement for adults. This FSSAI-approved product contains 26 essential vitamins, minerals, and botanicals for holistic nutritional support.
Apr 07 2026 15:04:00

Alkem Laboratories Limited

Alkem Laboratories launched A to Z Daily, an everyday multivitamin supplement for adults. The product is formulated with 26 essential vitamins, minerals, and botanicals, providing 100% RDA of 19 vitamins and minerals for holistic nutritional support.
Apr 07 2026 15:04:00

Alkem Laboratories Ltd - 539523 - Please Find Attached Herewith Intimation About Increase In Investment To Be Made For Setting Up Of Manufacturing Facility Of The Company In Ujjain, Madhya Pradesh.

Alkem Laboratories' board approved increasing investment for its Ujjain manufacturing facility to ₹1036 crores, up from the previously approved ₹533 crores. This strategic expansion will establish a new greenfield formulations plant in Madhya Pradesh, executed in a phased manner.
Apr 02 2026 13:04:00
Read More

About Alkem Laboratories AboutThe

NSE : 11703  
BSE : 539523  
ISIN : INE540L01014  

The Company was incorporated as a private limited company ?Alkem Laboratories Private Limited? on August 81973 at Patna under the Companies Act 1956 and subsequently became a deemed public limited company under section 43A(2) of Companies Act 1956 on October 26 1988. Pursuant to the Company passing a resolution under section 21 of Companies Act 1956 and upon issuance of a fresh certificate of incorporation consequent on change of name dated August 21 2001 the name of the Company was changed to ?Alkem Laboratories Limited? with effect from October 26 1988. the registered office was originally located at ?Exhibition Road Patna ? 800 001 Bihar India?. the Company filed Company Petition No. 356(17)/ ERB/ 2007 before the Company Law Board Eastern Region Bench at Kolkata for shifting the registered office of the Company from the State of Bihar to the State of Maharashtra as approved by a special resolution at its extra-ordinary general meeting held on January 29 2007. The Company Law Board Eastern Region Bench at Kolkata passed an order dated July 30 2007 whereby it confirmed the alteration of the situation clause in the Memorandum of Association from the State of Bihar to the State of Maharashtra. Pursuant to the order the registered office of the Company was shifted to ?Alkem House Senapati Bapat Marg Lower Parel Mumbai ? 400 013 Maharashtra India? with effect from August 2 2007.Major Events :1973-Incorporation of the Company. 1978-the Company established its first plant at Taloja Maharashtra. 1988-the Company became a deemed public limited company. 1992-the Company established its manufacturing facility in Mandwa Maharashtra. This facility was converted into an API facility in 2005. 1998-the Company established its Kachigam manufacturing facility in Gujarat. 2001-Startronic Pharmachem Private Limited and Indo Propkem amalgamated with the Company. 2002-the Company established its Amaliya manufacturing facility in Gujarat. 2003-the Company set up its research and development facility at Taloja Maharashtra. 2005-the Company established its manufacturing facility in Baddi Himachal Pradesh. 2006-the anti-infective drug Taxim became the first drug in the Indian pharmaceutical industry to cross 1000 million in terms of domestic sales in India (Source: IMS Research) 2007-the Company established its manufacturing facility in Kumrek Sikkim. -the Company filed its first ANDA in the United States for the drug Amlodipine. -the Company shifted its Registered Office from Patna Bihar to Mumbai Maharashtra. 2009-the Company acquired Pharmacor a generic pharma company in Australia. 2010-the Company acquired The PharmaNetwork LLC the holding company of Ascend Laboratories LLC. 2011-the Company acquired Enzene Bio sciences Limited. 2012-the Company acquired an API manufacturing facility in the United States. 2014-the Company acquired the Clindac. 2015-the Company acquired a formulation manufacturing facility in the United States. Awards and achievements: 2002-the Company was awarded the Pharma Business and Technology Excellence Award in 2002 as 'India?s Most Esteemed Pharmaceutical Company'2004-the product Taxim was awarded the Pharma Business and Technology Excellence Award for successful brand in 2004 2005-the Company was awarded the Overall Performance Award for Group B at the 5th Express Pharma Awards in 2005 2009-the Company received a certificate of appreciation for outstanding export performance in the category of formulations by the Pharmaceuticals Export Promotion Council of India supported by Ministry of Commerce and Industry GOI -the Company received the certificate of appreciation in the category of ?Formulation Experts? by the Pharmaceuticals Export Promotion Council of India supported by Ministry of Commerce and Industry GOI 2013-the Company was awarded the India?s most admired pharma company award for 2013 at the 6th Annual Pharmaceutical Leadership Summit in 2013 2014-the Product ?Clavam? was awarded as the ? Brand of the Year? at the AWACS Award 2014

Read More

Alkem Laboratories Management

NamePosition
Neela BhattacherjeeNon Executive Independent Director
Manish NarangPresident – Legal, Company Secretary & Compliance Officer
View More

Alkem Laboratories FAQs

Alkem Laboratories शेयर का खरीद मूल्य 5344 है। लाइव प्राइस और तत्काल ट्रेडिंग के लिए, आप अपने चॉइस ट्रेडिंग खाते में लॉगिन कर सकते हैं या चॉइस के साथ मुक्त डीमैट खाता खोल सकते हैं।

Alkem Laboratories शेयर खरीदने के लिए अपने चॉइस ट्रेडिंग खाते में लॉगिन करें, या चॉइस डीमैट खाता खोल, फिर फंड जोड़ें, कंपनी का नाम खोजें, अपना ऑर्डर टाइप चुनें और ट्रेड प्लेस करें।

Alkem Laboratories शेयर का प्राइस-टू-अर्निंग्स (पी/ई) रेशियो 26.37 है। आप सापेक्ष मूल्यांकन के लिए इसकी तुलना सेक्टर के औसत से कर सकते हैं।

Alkem Laboratories शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 4.47 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

Alkem Laboratories शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 3.5 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

Alkem Laboratories का मार्केट कैप 63895.54 CR है। यह कंपनी के आकार की श्रेणी और ट्रेडिंग लिक्विडिटी को दर्शाता है।

Alkem Laboratories शेयर का 52 सप्ताह का उच्चतम और न्यूनतम मूल्य 5933.50 और 4716.20 है। ये मूल्य मूल्य सीमाएं, ट्रेडिंग रेंज, अस्थिरता, संभावित सपोर्ट/रेजिस्टेंस और मूल्य गति को दर्शाते हैं।

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost